Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

On location

Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL

For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine, cyclophosphamide, rituximab), a fixed-duration regimen of venetoclax plus obinutuzumab...
On location

Fixed-Duration Ibrutinib, Venetoclax Oral Combination Effective in CLL/SLL

A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to...
On location

Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients with CLL

Geriatric domains of functional status, social activity, and nutritional status were associated with overall survival (OS) and progression-free survival (PFS) in older adults with...
How I Treat In Brief

Venetoclax-Based Treatments for Chronic Lymphocytic Leukemia

William G. Wierda, MD, PhD, and Francesco Paolo Tambaro, MD, PhD, review the role of venetoclax and other targeted therapies in the treatment of...
WIB_icon

Evaluating Ibrutinib in Patients With Heavily Pretreated Hairy Cell Leukemia

Treatment with ibrutinib offered durable disease control in patients with heavily pretreated classic and variant relapsed hairy cell leukemia (HCL) who were not expected...
WIB_icon

Acalabrutinib Induces Durable Remission in Patients With Treatment Naïve Chronic Lymphocytic Leukemia

Treatment with the next-generation covalent Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was safe and led to durable, long-term remission in a small group of...

Trilaciclib Approved for Chemotherapy-Induced Myelosuppression

The U.S. Food and Drug Administration (FDA) has approved trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, to reduce the frequency of bone marrow suppression in...

FDA Grants Breakthrough Therapy Designation to Asciminib for CML

The FDA has granted breakthrough therapy designation to asciminib, a first-in-class allosteric inhibitor specifically targeting the ABL myristoyl pocket (STAMP), for the treatment of...
On location

Durable Efficacy With LOXO-305 in Heavily Pretreated CLL/SLL

LOXO-305, a highly selective noncovalent Bruton tyrosine kinase (BTK) inhibitor, was associated with promising response and efficacy rates in patients with heavily pretreated and...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...
Advertisement

Current Issue

June 2021 Volume 7 Issue 7

This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.

Block title